Silk Road Medical Inc 's ROA from the second quarter of 2024 to the second quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Silk Road Medical Inc 's ROA in the second quarter of 2024?
Silk Road Medical Inc recorded a cumulative net loss of $-57 million during 12 months ending in the second quarter of 2024, resulting in a negative return on assets (ROA) of -21.53%.

However, within the Healthcare sector 384 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2024 quarter, so far to 3748, from total ROA ranking in the first quarter of 2024 at 3779.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter
Y / Y Total Assets Change	1.72 %	-2.93 %	-1.22 %	60.98 %	62.87 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-57	-53	-56	-55	-53
Return On Assets (TTM)	-21.53 %	-20.43 %	-21.16 %	-20.95 %	-22.09 %
SILK's Total Ranking	# 3748	# 3779	# 4364	# 3891	# 3972
Total Assets (TTM) in million	270	253	266	262	265
Seq. Total Assets Change	6.64 %	-5.1 %	1.81 %	-1.27 %	1.76 %
Seq. Net Income Change	-	-	-	-	-

SILK's 5 Years Annual ROA >> Back to SILK Management Effectiveness >> Compare SILK ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 121
Sector	# 385
Overall	# 3686

Return On Assets Statistics
High	Average	Low
-20.51 %	-28.33 %	-45.85 %
(Mar 31 2024)		(Dec 31 2019)

Financial Statements
Silk Road Medical Inc 's Assets	$ 270 million	SILK's Balance sheet
Silk Road Medical Inc 's Income	$ -17 million	Quarterly SILK's Income Statement
SILK's Income by Division		See SILK's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	-1.22 %	72.19 %	-67.09 %	246.36 %	-
Total Assets in million	266	270	157	476	137
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-56	-55	-50	-47	-52
Annual Return On Assets	-20.92 %	-20.4 %	-31.8 %	-9.95 %	-38.15 %

SILK's 5 Years Annual ROA >> Back to SILK Management Effectiveness >> Compare SILK ROA to its Competitors

More Return On Assets Ratios
SILK's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SILK's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SILK's Competitors
Subscribers only: Roa for Silk Road Medical Inc 's Suppliers
Subscribers only: Return On Assets for SILK's Customers

You may also want to know
SILK's Roi	SILK's Inventory Turnover Ratio	SILK's Growth Rates	SILK's Dividend Comparisons
	SILK's Profitability Ratios	SILK's Asset Turnover Ratio	SILK's Dividend Growth
SILK's Roe	SILK's Valuation Ratios	SILK's Financial Strength Ratios	SILK's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:36:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.